What You Need To Know
Dr. Nathaniel Lebowitz, who leads preventive cardiology at Hackensack University Medical Center, was recently interviewed by Cardiovascular Business about the growing focus on lipoprotein(a), or Lp(a), a critical and often overlooked genetic driver of heart attacks and strokes.
In the interview, Dr. Lebowitz discusses why Lp(a) is a "major, major killer" and frequently the missing link in patients who suffer cardiovascular events without traditional risk factors. He explains its role as a "risk elevator," the latest screening guidelines from the AHA and ACC, and why testing is crucial for at-risk individuals.
Dr. Lebowitz also shares insights into the exciting future of treatment, with novel therapies like small interfering RNA (siRNA) agents currently in late-stage trials. He details his work with the American Heart Association's national Lp(a) Discovery Project, an initiative aimed at boosting awareness and standardizing care as these new drugs approach the market.
Click here to read the full interview to learn more about Dr. Lebowitz's expert perspective on identifying and managing patients with elevated Lp(a) and what the future holds for treatment.